HK:1541 Stock Latest News
Company AnnouncementsImmuneOnco Switches Auditor After Fee Dispute Tied to Subsidiary Expansion2w ago1541
Company AnnouncementsImmuneOnco reshapes board with resignation and proposed appointment of independent director2M ago1541
Company AnnouncementsImmuneOnco Starts Phase II Trial of Dual-Immunotherapy Combo for Advanced Liver Cancer2M ago1541
Company AnnouncementsImmuneOnco Advances Lead Leukemia Drug to Fully Enrolled Phase III Trial2M ago1541
Company AnnouncementsImmuneOnco Advances PAH Candidate IMC-003 With First Patient Dosed and Phase I Enrolment Completed2M ago1541
Company AnnouncementsImmuneOnco Wins FDA Nod to Test Bispecific IMM0306 in Lupus Trial2M ago1541Company AnnouncementsImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend3M ago1541
Company AnnouncementsImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection3M ago1541
- Company AnnouncementsImmuneOnco Details ESOP-Linked Capital Increase at Non-Oncology Subsidiary3M ago1541
Company AnnouncementsImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease4M ago1541- Company AnnouncementsImmuneOnco flagged by HKEX over shareholder loan compliance4M ago1541
- Company AnnouncementsImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection4M ago1541
Company AnnouncementsImmuneOnco Deploys HK$87.5 Million Into Vital Ventures Cash Management Funds4M ago1541Company AnnouncementsImmuneOnco plans on-market H-share buyback to signal confidence and boost value5M ago1541
Company AnnouncementsImmuneOnco Shareholders Approve All AGM Resolutions and Grant New Capital Mandates5M ago1541
Company AnnouncementsImmuneOnco Rotates HK$205m Wealth Product Into Larger HK$212m Placement5M ago1541
Company AnnouncementsImmuneOnco Begins Phase II Trial of First-in-Class CD47/CD20 Bispecific IMM0306 for Lupus5M ago1541- Company AnnouncementsImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate6M ago1541
Company AnnouncementsImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma7M ago1541
Company AnnouncementsImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data7M ago1541Company AnnouncementsImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM017M ago1541
Company AnnouncementsImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results8M ago1541